Cargando…

Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2

Cost-effective, efficacious therapeutics are urgently needed to combat the COVID-19 pandemic. In this study, we used camelid immunization and proteomics to identify a large repertoire of highly potent neutralizing nanobodies (Nbs) to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Yufei, Nambulli, Sham, Xiao, Zhengyun, Liu, Heng, Sang, Zhe, Duprex, W. Paul, Schneidman-Duhovny, Dina, Zhang, Cheng, Shi, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2020
Materias:	Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857400/ https://www.ncbi.nlm.nih.gov/pubmed/33154108 http://dx.doi.org/10.1126/science.abe4747

Ejemplares similares

Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2
por: Xiang, Yufei, et al.
Publicado: (2020)

Superimmunity by pan-sarbecovirus nanobodies
por: Xiang, Yufei, et al.
Publicado: (2022)

A resource of high-quality and versatile nanobodies for drug delivery
por: Shen, Zhuolun, et al.
Publicado: (2021)

Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes
por: Sun, Dapeng, et al.
Publicado: (2021)

Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes
por: Sun, Dapeng, et al.
Publicado: (2021)

Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
por: Nambulli, Sham, et al.
Publicado: (2021)

NanoNet: Rapid and accurate end-to-end nanobody modeling by deep learning
por: Cohen, Tomer, et al.
Publicado: (2022)

Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine–Nanobody Complex
por: Desmyter, Aline, et al.
Publicado: (2017)

A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529)
por: Lu, Yuying, et al.
Publicado: (2023)

The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor
por: Brielle, Esther S., et al.
Publicado: (2020)

Developing lectins as inhibitors of SARS-CoV2
por: Guseman, Alex J., et al.
Publicado: (2022)

Predicting structures of large protein assemblies using combinatorial assembly algorithm and AlphaFold2
por: Shor, Ben, et al.
Publicado: (2023)

Generation of Multivalent Nanobody-Based Proteins with Improved Neutralization of Long α-Neurotoxins from Elapid Snakes
por: Wade, Jack, et al.
Publicado: (2022)

Abstract 1509: Targeting Spike Glycans to Inhibit SARS-CoV-2 Viral Entry
por: Guseman, Alex, et al.
Publicado: (2023)

CAMEL NANOBODIES NEUTRALIZE SARS-COV-2 VARIANTS
por: Hong, Jessica, et al.
Publicado: (2023)

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
por: Koenig, Paul-Albert, et al.
Publicado: (2021)

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein
por: Lu, Qizhong, et al.
Publicado: (2021)

Identification of New DR5 Agonistic Nanobodies and Generation of Multivalent Nanobody Constructs for Cancer Treatment
por: Sadeghnezhad, Golnaz, et al.
Publicado: (2019)

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2
por: Pymm, Phillip, et al.
Publicado: (2022)

Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials
por: Sánchez-García, Laura, et al.
Publicado: (2021)

Reduced antigenicity of Omicron lowers host serologic response
por: Tubiana, Jérôme, et al.
Publicado: (2022)

Reduced B cell antigenicity of Omicron lowers host serologic response
por: Tubiana, Jérôme, et al.
Publicado: (2022)

Prospects of Neutralizing Nanobodies Against SARS-CoV-2
por: Chen, Fangfang, et al.
Publicado: (2021)

Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice
por: Liu, Honghui, et al.
Publicado: (2023)

FoXS: a web server for rapid computation and fitting of SAXS profiles
por: Schneidman-Duhovny, Dina, et al.
Publicado: (2010)

Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies
por: Stefan, Maxwell A., et al.
Publicado: (2021)

Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers
por: Rujas, Edurne, et al.
Publicado: (2021)

Integrative structural modeling with small angle X-ray scattering profiles
por: Schneidman-Duhovny, Dina, et al.
Publicado: (2012)

Llamanade: an open-source computational pipeline for robust nanobody humanization
por: Sang, Zhe, et al.
Publicado: (2021)

Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment
por: Wang, Jiewen, et al.
Publicado: (2022)

A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies
por: Chen, Xun, et al.
Publicado: (2021)

Camel nanobodies broadly neutralize SARS-CoV-2 variants
por: Hong, Jessica, et al.
Publicado: (2021)

Structural basis of nanobodies neutralizing SARS-CoV-2 variants
por: Shi, Zhenzhong, et al.
Publicado: (2022)

Nanobodies that Neutralize HIV
por: Weiss, Robin A., et al.
Publicado: (2019)

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
por: McCarthy, Kevin R., et al.
Publicado: (2021)

Isolation of an escape-resistant SARS-CoV-2 neutralizing nanobody from a novel synthetic nanobody library
por: Dormeshkin, Dmitri, et al.
Publicado: (2022)

Nanobodies as Versatile Tool for Multiscale Imaging Modalities
por: Erreni, Marco, et al.
Publicado: (2020)

An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
por: Hanke, Leo, et al.
Publicado: (2020)

The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization
por: Zebardast, Arghavan, et al.
Publicado: (2021)

Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants
por: Hong, Jessica, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ma39hqi72mbpraa8fio92sv1od